Chronic myeloid leukemia as a stem cell-derived malignancy
Archives of Advances in Biosciences,
Vol. 3 No. 2 (2012),
17 June 2012
https://doi.org/10.22037/jps.v3i2.3479
Abstract
Chronic myeloid leukemia (CML) is a myeloproliferative disease of the hematopoietic stem cells, characterized by the presence of the Philadelphia (Ph) chromosome. Although imatinib inhibits the BCR-ABL kinase activity, clinical experiences confirm that imatinib may not target CML stem cells in vivo. The identification of signaling pathways responsible for the self-renewal properties of leukemic stem cells in CML will help in the discovery of novel therapeutic targets. Here we review signaling pathways including Wnt/β-catenin, Hedgehog, Alox5, and Foxo which play crucial roles in the maintenance of stem cell functions in CML. It is thought that inhibition of key genes that are part of self-renewal associated signaling pathways may provide an effective way to reduce aberrant stem cell renewal in CML.
Keywords:
- cancer stem cells
- chronic myeloid leukemia stem cells
- signaling pathway
- microRNA
How to Cite
Babashah, S., Rezaei-Tavirani, M., Zamanian-Azodi, M., & Saki, N. (2012). Chronic myeloid leukemia as a stem cell-derived malignancy. Archives of Advances in Biosciences, 3(2). https://doi.org/10.22037/jps.v3i2.3479
- Abstract Viewed: 340 times
- PDF Downloaded: 168 times